LATEST ARTICLES

8th Plenary Meeting EHDN 2014 Barcelona: 19-21 settembre 2014 – Report

Annarita Bentivoglio* - Marina Frontali** Si è appena concluso l’ottavo meeting plenario del Network Europeo per la Malattia di Huntington. Oltre 900 partecipanti: l’incontro più numeroso che sia stato mai organizzato sulla Malattia di Huntington. Un...

Fatal cellular malfunction identified in Huntington’s disease

Researchers believe they have learned how mutations in the gene that causes Huntington’s disease kill brain cells, a finding that could open new opportunities for treating the fatal disorder. Scientists first linked the gene...

Vaccinex Provides Update of Potentially Pivotal SIGNAL Clinical Trial in Huntington’s Disease

Topline data anticipated in October 2020 as previously guided ROCHESTER, N.Y., July 07, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in Huntington’s disease (HD) and cancer, today announced that,...

Ohio State Conducts First Gene Therapy Clinical Trial For Huntington’s Disease

COLUMBUS, Ohio – In a worldwide first, surgeons at The Ohio State University Wexner Medical Center have treated two patients with Huntington’s disease using a novel gene therapy treatment as part of a multi-center, double-blind randomized...

Novel pathology could improve diagnosis and treatment of Huntington’s and other diseases

Bristol scientists have discovered a novel pathology that occurs in several human neurodegenerative diseases, including Huntington’s disease. The article, published in Brain Pathology, describes how SAFB1 expression occurs in both spinocerebellar ataxias and Huntington's disease and...

Changing jobs: converting other cell types into neurons

Because HD causes a loss of neurons in the brain, some researchers are exploring ways to replace them. Working with HD mice, scientists recently showed that supportive brain cells called glia can be coaxed...

uniQure Announces First Two Patients Treated in Phase I/II Clinical Trial of AMT-130 for...

~ Milestone Marks the First-in-Human AAV Gene Therapy Trial for Huntington’s Disease ~ LEXINGTON, Mass. and AMSTERDAM, June 19, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients...